Novavax (NVAX) Other Non-Current Liabilities (2010 - 2026)

Novavax's Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $193.2 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 38.4% year-over-year to $193.2 million; the TTM figure through Mar 2026 stood at $193.2 million (down 38.4% YoY), while the FY2025 annual figure was $239.1 million, down 33.52% from the prior year.
• Other Non-Current Liabilities was $193.2 million for Q1 2026 at Novavax, down from $239.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $359.6 million in Q4 2024 to a low of $33.1 million in Q4 2023.
• Historically, Other Non-Current Liabilities has averaged $182.9 million across 5 years, with a median of $193.2 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities tumbled 62.16% in 2023, then surged 985.46% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $55.7 million in 2022, then slumped by 40.52% to $33.1 million in 2023, then soared by 985.46% to $359.6 million in 2024, then slumped by 33.52% to $239.1 million in 2025, then retreated by 19.17% to $193.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $193.2 million (Q1 2026), $239.1 million (Q4 2025), and $263.5 million (Q3 2025), per Business Quant data.